ABL is Pleased to Announce the TherapyEdge ViroScore Suite Platform is Now Available in Brazil.LUXEMBOURG & SAO Sa´o n. 1. (Zool.) Any marine annelid of the genus Hyalinæcia, especially H. tubicola of Europe, which inhabits a transparent movable tube resembling a quill in color and texture. PAULO, Brazil -- Advanced Biological Laboratories (ABL) and Centro de Genomas are pleased to announce an agency agreement whereby Centro de Genomas will provide to the private and public sectors throughout Brazil, the ABL TherapyEdge products in Portuguese language Portuguese language, member of the Romance group of the Italic subfamily of the Indo-European family of languages (see Romance languages). It is the mother tongue of about 170 million people, chiefly in Portugal and the Portuguese islands in the Atlantic (11 million . Beginning immediately Centro de Genomas will be supporting TherapyEdge[TM], ViroScore Suite[TM] and other online services primarily in the field of HIV/AIDS and viral hepatitis viral hepatitis n. Any of various forms of hepatitis caused by a virus. viral hepatitis, n an inflammatory condition of the liver, caused by the hepatitis viruses: A, B, C, delta, E, F, G, or H. . Through the agreement, Centro de Genomas will provide the advanced technical support and customer care that ABL TherapyEdge customers have come to appreciate and value highly. Centro de Genomas will offer customers expanded training and support via workshops and in-office training. ABL and Centro de Genomas will work closely to develop strategic partnerships in Brazil. The combined alliance will seek to find a national or a regional corporate Diagnostic distributor for ABL's products line. In accordance with its full commitment to support research, which include free medical tools and exchange of knowledge for the benefit of humanity, ABL has proposed Centro de Genomas to be in contact with any researcher, university and non-profit institution in Brazil to offer them royalty free sublicense rights on ABL US patents (Barry et al 6.081.786, 6.188.988 and their foreign equivalents including the ones prosecuted in Brazil). "We're extremely pleased about this new partnership. We believe Brazilian infectious diseases specialists and patients will see the benefits of an integrated IT solution such as TherapyEdge. We have now TherapyEdge customized for the Brazilian market which should ease its widespread use," said Dr Chalom Sayada, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of ABL. "ABL is the ideal company to partner with us. The electronic medical records market and online services is growing rapidly and fulfills important needs for integrated disease management in complex diseases such as HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and viral hepatitis. It is completing our offer for advanced healthcare technologies," said Mrs Cinthia Vilhena, CEO of Centro de Genomas. "The TherapyEdge ViroScore platform will offer Brazilian clinicians, virologists and epidemiologists with a suite of comprehensive tools to support their clinical routine but also their research from therapeutics to genomics," said Dr Ricardo Sobhie Diaz, Medical Director of Centro de Genomas. More information about ABL at www.ablsa.com and Centro de Genomas at www.centrodegenomas.com.br |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion